Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web


  Free Subscription


1 Acta Haematol
1 Am J Hematol
1 Ann Hematol
2 Biochem Biophys Res Commun
3 Blood
1 BMC Cancer
1 Bone Marrow Transplant
4 Cancer
2 Eur J Haematol
1 Int J Hematol
1 J Pediatr Hematol Oncol
1 Leuk Lymphoma
6 Leuk Res
3 Leukemia
2 Oncogene
3 PLoS One
1 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Acta Haematol

  1. JIANG L, Deng T, Wang D, Xiao Y, et al
    Elevated Serum Exosomal miR-125b Level as a Potential Marker for Poor Prognosis in Intermediate-Risk Acute Myeloid Leukemia.
    Acta Haematol. 2018;140:183-192.
    PubMed     Text format     Abstract available

    Am J Hematol

  2. HEHLMANN R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, et al
    Tyrosine Kinase Inhibitor Interruptions, Discontinuations and Switching in Patients with Chronic-Phase Chronic Myeloid Leukemia in Routine Clinical Practice: SIMPLICITY.
    Am J Hematol. 2018 Oct 5. doi: 10.1002/ajh.25306.
    PubMed     Text format     Abstract available

    Ann Hematol

  3. BODDU P, Chihara D, Masarova L, Pemmaraju N, et al
    The co-occurrence of driver mutations in chronic myeloproliferative neoplasms.
    Ann Hematol. 2018;97:2071-2080.
    PubMed     Text format     Abstract available

    Biochem Biophys Res Commun

  4. LI Y, Hu J, Song H, Wu T, et al
    Antibiotic anisomycin selectively targets leukemia cell lines and patient samples through suppressing Wnt/beta-catenin signaling.
    Biochem Biophys Res Commun. 2018 Oct 6. pii: S0006-291X(18)32124.
    PubMed     Text format     Abstract available

  5. WANG Y, Fu L, Sun A, Tang D, et al
    C/EBPbeta contributes to transcriptional activation of long non-coding RNA NEAT1 during APL cell differentiation.
    Biochem Biophys Res Commun. 2018;499:99-104.
    PubMed     Text format     Abstract available


  6. HILL JA, Li D, Hay KA, Green ML, et al
    Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
    Blood. 2018;131:121-130.
    PubMed     Text format     Abstract available

  7. ZHANG J, Zhang Y, Zhang M, Liu C, et al
    FLT3 pathway is a potential therapeutic target for PRC2 mutated T cell acute lymphoblastic leukemia.
    Blood. 2018 Oct 3. pii: blood-2018-04-845628. doi: 10.1182/blood-2018-04-845628.
    PubMed     Text format    

  8. EL ASHKAR S, Schwaller J, Pieters T, Goossens S, et al
    LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis.
    Blood. 2018;131:95-107.
    PubMed     Text format     Abstract available

    BMC Cancer

  9. YU H, Zhang H, Yang J, Liu C, et al
    Health utility scores of family caregivers for leukemia patients measured by EQ-5D-3L: a cross-sectional survey in China.
    BMC Cancer. 2018;18:950.
    PubMed     Text format     Abstract available

    Bone Marrow Transplant

  10. MOUKALLED NM, El Darsa H, Haibe Y, Massoud R, et al
    Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation.
    Bone Marrow Transplant. 2018 Oct 4. pii: 10.1038/s41409-018-0347.
    PubMed     Text format    


  11. JABBOUR E, Sasaki K, Ravandi F, Huang X, et al
    Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Cancer. 2018 Oct 11. doi: 10.1002/cncr.31720.
    PubMed     Text format     Abstract available

  12. PUI CH
    To delay or not to delay, that is the question for patients with acute lymphoblastic leukemia who do not receive prophylactic cranial irradiation.
    Cancer. 2018 Oct 10. doi: 10.1002/cncr.31756.
    PubMed     Text format    

  13. YEH TC, Liang DC, Hou JY, Jaing TH, et al
    Treatment of childhood acute lymphoblastic leukemia with delayed first intrathecal therapy and omission of prophylactic cranial irradiation: Results of the TPOG-ALL-2002 study.
    Cancer. 2018 Oct 10. doi: 10.1002/cncr.31758.
    PubMed     Text format     Abstract available

  14. TRUONG TH, Pole JD, Barber R, Dix D, et al
    Enrollment on clinical trials does not improve survival for children with acute myeloid leukemia: A population-based study.
    Cancer. 2018 Oct 6. doi: 10.1002/cncr.31728.
    PubMed     Text format     Abstract available

    Eur J Haematol

  15. ZACHARAKI D, Ghazanfari R, Li H, Lim HC, et al
    Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
    Eur J Haematol. 2018;101:57-67.
    PubMed     Text format     Abstract available

  16. ARCIONI F, Roncadori A, Di Battista V, Tura S, et al
    Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
    Eur J Haematol. 2018;101:78-85.
    PubMed     Text format     Abstract available

    Int J Hematol

  17. HARADA K, Sekiya N, Ikegawa S, Sasaki S, et al
    Cytomegalovirus meningitis in a patient with relapsed acute myeloid leukemia.
    Int J Hematol. 2018 Oct 5. pii: 10.1007/s12185-018-2544.
    PubMed     Text format     Abstract available

    J Pediatr Hematol Oncol

  18. DOHERTY EE, Schallert EK, Stevens AM, Punia JN, et al
    Acute Megakaryoblastic Leukemia With Diffuse Periosteal Reaction of Bilateral Lower Extremities.
    J Pediatr Hematol Oncol. 2018 Oct 9. doi: 10.1097/MPH.0000000000001299.
    PubMed     Text format     Abstract available

    Leuk Lymphoma

  19. MEI C, Ren Y, Zhou X, Ye L, et al
    Clinical and biological characteristics of acute myeloid leukemia with 20-29% blasts: a retrospective single-center study.
    Leuk Lymphoma. 2018 Oct 10:1-10. doi: 10.1080/10428194.2018.1515938.
    PubMed     Text format     Abstract available

    Leuk Res

  20. BRASSESCO MS, Pezuk JA, Cortez MA, Bezerra Salomao K, et al
    TLE1 as an indicator of adverse prognosis in pediatric acute lymphoblastic leukemia.
    Leuk Res. 2018;74:42-46.
    PubMed     Text format     Abstract available

  21. BRUNNER AM, Kim PG, Sadrzadeh H, Drapkin BJ, et al
    Clustered incidence of adult acute promyelocytic leukemia.
    Leuk Res. 2018;74:47-50.
    PubMed     Text format    

  22. CHONG ML, Cheng H, Xu P, You H, et al
    TFG-RARA: A novel fusion gene in acute promyelocytic leukemia that is responsive to all-trans retinoic acid.
    Leuk Res. 2018;74:51-54.
    PubMed     Text format    

  23. ESKAZAN AE, Tiribelli M
    Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?
    Leuk Res. 2018;74:55-56.
    PubMed     Text format    

  24. JAMY O, Bae S, Costa LJ, Erba HP, et al
    Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow.
    Leuk Res. 2018;74:64-67.
    PubMed     Text format     Abstract available

  25. BONIFACIO M, Scaffidi L, Binotto G, Miggiano MC, et al
    Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy.
    Leuk Res. 2018;74:75-79.
    PubMed     Text format     Abstract available


  26. WALKER CJ, Oakes CC, Genutis LK, Giacopelli B, et al
    Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0281.
    PubMed     Text format    

  27. YAN B, Chen Q, Shimada K, Tang M, et al
    Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0279.
    PubMed     Text format     Abstract available

  28. MANSO BA, Zhang H, Mikkelson MG, Gwin KA, et al
    Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0280.
    PubMed     Text format     Abstract available


  29. CHONG PSY, Zhou J, Chooi JY, Chan ZL, et al
    Non-canonical activation of beta-catenin by PRL-3 phosphatase in acute myeloid leukemia.
    Oncogene. 2018 Oct 10. pii: 10.1038/s41388-018-0526.
    PubMed     Text format     Abstract available

  30. MCLEAN K, Tan L, Bolland DE, Coffman LG, et al
    Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.
    Oncogene. 2018 Oct 10. pii: 10.1038/s41388-018-0523.
    PubMed     Text format     Abstract available

    PLoS One

  31. IBANEZ M, Carbonell-Caballero J, Such E, Garcia-Alonso L, et al
    The modular network structure of the mutational landscape of Acute Myeloid Leukemia.
    PLoS One. 2018;13:e0202926.
    PubMed     Text format     Abstract available

  32. HATTORI H, Ishikawa Y, Kawashima N, Akashi A, et al
    Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia.
    PLoS One. 2018;13:e0204850.
    PubMed     Text format     Abstract available

  33. BRESIN A, Ragone G, Cristofoletti C, Arcelli D, et al
    T Cell Leukemia/Lymphoma 1A is essential for mouse epidermal keratinocytes proliferation promoted by insulin-like growth factor 1.
    PLoS One. 2018;13:e0204775.
    PubMed     Text format     Abstract available

    Proc Natl Acad Sci U S A

  34. KATSUMURA KR, Mehta C, Hewitt KJ, Soukup AA, et al
    Human leukemia mutations corrupt but do not abrogate GATA-2 function.
    Proc Natl Acad Sci U S A. 2018 Oct 9. pii: 1813015115.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.